RAPPORT THERAPEUTICS INC

RAPPNASDAQ

🏆 #2147 by market capEarnings Nov 4US Equity

$33.06▼ $0.34 (−1.03%)

After hours · at close

🔔

Track RAPP

Get earnings, price moves & breaking news on Telegram

Track

24h▼ 1.0%

7d▼ 20.3%

14d▼ 22.6%

30d▼ 32.3%

ytd▲ 8.9%

1y▲ 18.1%

🏦Market Cap

$1.58B

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

—

Otter Score

Fair

Trading Snapshot

Day Range: $32.58 – $33.37
52-Week Range: $23.75 – $52.93
Volume: $2.13B
Avg Volume: $2.10B
Shares Outstanding: 47.8M
Next Earnings: Nov 7, 2026

Fundamentals Snapshot

Annual Revenue: $310M
Last Q Revenue: $71M
P/E Ratio: —
P/S Ratio: —
EPS (TTM): $-3.04
Dividend Yield: —
Dilution (1yr): +143.6%

Why Investors Own RAPP

✓High-growth profile — revenue up +2.4% YoY with expanding US Equity exposure.
✓Healthy economics — 64% gross margin and 27% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

RAPPORT THERAPEUTICS INC

RAPP

Financial Trends

Revenue

$0▲ +0.0% YoY

Operating Income

−$125M▲ +50.6% YoY

Free Cash Flow

−$88M▲ +31.0% YoY

Shares Outstanding

47.0M▲ +143.6% YoY

Net Cash

$41M▼ −$14M YoY

StockOtter · stockotter.space

About RAPPORT THERAPEUTICS INC

Rapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical enterprise, concentrating its efforts on discovering and developing innovative small-molecule therapeutics for individuals living with central nervous system (CNS) disorders. Its flagship product candidate, RAP-219, is an experimental small molecule precisely designed to inhibit TARPy8-containing AMPARs with exceptional potency (picomolar affinity). This promising compound aims to treat focal epilepsy and a range of other neurological conditions, including peripheral neuropathic pain and bipolar disorder. The company's pipeline further includes RAP-199, another molecule targeting TARPy8, which boasts distinct chemical and pharmacokinetic profiles. Moreover, Rapport is advancing several nicotinic acetylcholine receptor (nAChR) programs, such as an a6 nAChR therapy for chronic pain and an a9a10 nAChR treatment intended for hearing impairments. Formed in 2022 under the initial name Precision Neuroscience NewCo, Inc., the company adopted its current identity as Rapport Therapeutics, Inc. in October 2022, and its operations are based in Boston, Massachusetts.

🦦